new drugs

Mai 13, 2021 1:00AM

Timely Access to New Pharmaceuticals in Canada, the United States, and the European Union

Bacchus Barua, Will Westcott, Van Nghiem Vo

Étiquettes:

access to medicines, access to new drugs, access to new medicine, new prescription drugs, new drug approval, new drug regulations, new drugs, pharmaceutical

Juillet 22, 2013 2:00AM

Stronger intellectual property for pharmaceuticals would benefit Canadians

Nadeem Esmail

Canada's lagging intellectual property (IP) protections for pharmaceutical innovators are a key issue to be settled in the Comprehensive Economic and Trade Agreement (CETA) negotiations with the European Union. They may also play a role in upcoming negotiations for the multi-country Trans-Pacific Partnership (TPP). Two new essays on the cost and benefits of stronger protection suggest Canadians would be far better off, in both economic and health terms, with an IP protection regime for pharmaceutical innovators that was more closely aligned with international standards.

Étiquettes:

intellectual property rights, pharmaceutical industry, intellectual property for pharmaceuticals, new medicine, new drugs, property rights, trade, CETA, TPP, trans-pacific partnership

Avril 13, 2012 2:00AM

Easy access to new prescription drugs depends on where you live

Mark Rovere

Question: Should patients in Rome or Detroit have faster access to new prescription drugs than someone living in Victoria or Windsor? If your answer to that is no, then here is another query: Why do government agencies tasked to approve or deny new drugs in Europe and the United States (and which presumably have the same high standards as Canada) act quicker when compared to Health Canada?

Étiquettes:

prescription drugs, new medicine, new drugs, drug approval process, health canada, FDA, EMA, european medicine agency, american food and drug adminstration

Avril 4, 2012 2:00AM